497 related articles for article (PubMed ID: 34445669)
1. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SARS-CoV-2 viral entry upon blocking N- and O-glycan elaboration.
Yang Q; Hughes TA; Kelkar A; Yu X; Cheng K; Park S; Huang WC; Lovell JF; Neelamegham S
Elife; 2020 Oct; 9():. PubMed ID: 33103998
[TBL] [Abstract][Full Text] [Related]
3. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
4. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
[TBL] [Abstract][Full Text] [Related]
5. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
8. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
Li J; Wang P; Tracey KJ; Wang H
Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
[TBL] [Abstract][Full Text] [Related]
9.
Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
11. Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor.
Kim YS; Chung HS; Noh SG; Lee B; Chung HY; Choi JG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445310
[TBL] [Abstract][Full Text] [Related]
12. P21-activated kinase 1 (PAK1)-mediated cytoskeleton rearrangement promotes SARS-CoV-2 entry and ACE2 autophagic degradation.
Liu M; Lu B; Li Y; Yuan S; Zhuang Z; Li G; Wang D; Ma L; Zhu J; Zhao J; Chan CC; Poon VK; Chik KK; Zhao Z; Xian H; Zhao J; Zhao J; Chan JF; Zhang Y
Signal Transduct Target Ther; 2023 Oct; 8(1):385. PubMed ID: 37806990
[TBL] [Abstract][Full Text] [Related]
13. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
14. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
15. Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2.
Liu Y; Hu G; Wang Y; Ren W; Zhao X; Ji F; Zhu Y; Feng F; Gong M; Ju X; Zhu Y; Cai X; Lan J; Guo J; Xie M; Dong L; Zhu Z; Na J; Wu J; Lan X; Xie Y; Wang X; Yuan Z; Zhang R; Ding Q
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33658332
[TBL] [Abstract][Full Text] [Related]
16. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
[TBL] [Abstract][Full Text] [Related]
17. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
18. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
[TBL] [Abstract][Full Text] [Related]
19. Kidney organoids reveal redundancy in viral entry pathways during ACE2-dependent SARS-CoV-2 infection.
Vanslambrouck JM; Neil JA; Rudraraju R; Mah S; Tan KS; Groenewegen E; Forbes TA; Karavendzas K; Elliott DA; Porrello ER; Subbarao K; Little MH
J Virol; 2024 Mar; 98(3):e0180223. PubMed ID: 38334329
[TBL] [Abstract][Full Text] [Related]
20. Integrin mediates cell entry of the SARS-CoV-2 virus independent of cellular receptor ACE2.
Liu J; Lu F; Chen Y; Plow E; Qin J
J Biol Chem; 2022 Mar; 298(3):101710. PubMed ID: 35150743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
